Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules…
Pharmaceuticals, Biotechnology and Life Sciences
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules…
ATHENS, Greece & BELOIT, Wisc.–(BUSINESS WIRE)–BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research,…
Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved…
PLANTATION, Fla.–(BUSINESS WIRE)–#NationsBenefits—NationsBenefits, the leading healthcare fintech and supplemental benefits platform, announced a new partnership with Kinney Drugs, a trusted,…
TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural…
– Regulatory submission is based on positive results from the Phase 2 PROSPECT Study — – FDA sets PDUFA Date…
SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today…
Iberdomide has the potential to be the first approved CELMoD agent The U.S. FDA has granted Breakthrough Therapy Designation and…
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal…
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect…